Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $11.70, but opened at $12.16. Gyre Therapeutics shares last traded at $12.71, with a volume of 46,205 shares traded.
Gyre Therapeutics Stock Performance
The stock's 50 day moving average is $13.50 and its two-hundred day moving average is $12.80.
Institutional Trading of Gyre Therapeutics
A number of large investors have recently bought and sold shares of the business. FMR LLC acquired a new stake in shares of Gyre Therapeutics in the 3rd quarter worth $47,000. Barclays PLC lifted its stake in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after acquiring an additional 6,855 shares during the period. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter worth $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter worth $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter worth $218,000. Institutional investors and hedge funds own 23.99% of the company's stock.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
